Cipla's net profit declined by 35% year-on-year in the second quarter of fiscal year 2027, while the company invested ₹423 crore in research and development. Despite the profit drop, Cipla's global revenues reached ₹7,404 crore, showing a 4% sequential growth quarter-on-quarter.
- Global revenues stood at ₹7,404 crore, down 2.4% year-on-year.
- EBITDA decreased by 27% year-on-year to ₹1,388 crore.
- EBITDA margin contracted to 18.75% from 24.96% year-on-year.
- One-India business achieved highest quarterly sales with 12% growth.
- North America revenue was $172 million, continuing growth.
- Investment in R&D was ₹423 crore, 5.7% of sales.
- Net cash position was ₹9,823 crore with manageable debt.
What were Cipla's key financial results in Q2 FY27?
In Q2 FY27, Cipla's total revenue from operations was ₹7,404 crore, a 2.4% decrease compared to ₹7,589 crore in the same quarter of the previous year. The earnings before interest, taxes, depreciation, and amortisation (EBITDA) declined 27% to ₹1,388 crore from ₹1,894 crore year-on-year. The EBITDA margin reduced to 18.75% from 24.96% in Q2 FY26. However, sequentially, the company saw a 4% growth in global revenues and a 200 basis points increase in EBITDA margin quarter-on-quarter.
How did Cipla's business segments perform?
The One-India business recorded its highest quarterly sales ever, growing 12% year-on-year. In North America, Cipla reported quarterly revenue of $172 million, maintaining its growth trend. The South African private market business in One Africa grew approximately 1.3 times faster than the market. The Emerging Markets and Europe segment generated $101 million in revenue despite geopolitical challenges. Cipla's branded prescription business showed strong growth, with key therapies outperforming the market.
What investments did Cipla make in research and development?
Cipla invested ₹423 crore in research and development during Q2 FY27, which accounted for 5.7% of its sales. These investments were mainly directed towards product filings and key development programs to strengthen the company's product pipeline and support future growth.
What is Cipla's financial position and outlook?
The company reported a net cash position of ₹9,823 crore. Its debt primarily consists of lease liabilities and working capital requirements. Cipla's management emphasized a focus on sustained growth in core businesses, productivity improvements, and pipeline strengthening to provide high-quality medicines to patients.
How did Cipla's stock perform following the results?
After the earnings announcement, Cipla's shares declined by 1.4%, trading at ₹1,336 on the National Stock Exchange. The stock opened at ₹1,352.10, reached a high of ₹1,372.70, and a low of ₹1,334.70 during the day. Since the start of the year, Cipla shares have fallen 12%, with a 4% decline over the past month and a slight 0.6% increase in the last six months. The stock's 52-week high was ₹1,593.80 on October 27, 2025, and the low was ₹1,165.70 on April 2, 2026.
Frequently Asked Questions
Q: What caused Cipla's net profit decline in Q2 FY27?
A: The decline was mainly due to lower EBITDA and margin contraction compared to the previous year, despite revenue growth in some segments.
Q: How much did Cipla invest in research and development?
A: Cipla invested ₹423 crore in R&D during Q2 FY27, which is 5.7% of its sales.
Q: What are Cipla's plans for future growth?
A: The company plans to focus on core business growth, improve productivity, and strengthen its product pipeline to serve patients with trusted medicines.
